SUPN News and Press, Supernus Pharmaceuticals Inc. From 08/11/20

Second quarter total revenue is estimated to be $126.7 million, a 21% increase over 2019 Net product sales of Trokendi XR® and Oxtellar XR® are estimated to be $113.4 million, an 11% increase over 2019 Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020 ...

Introduction To keep myself sharp and my skills honed, I routinely go to my library of investment books and re-read classics that have had an impact on me. This week, I did a complete re-read of Joel Greenblatt's classic "The Little Book That Beats The Market." For any of you that are not ...

Image Source It has been another extremely strong quarter for AIG's Fund, as our diversified portfolio returned 29.46% in Q2 2020. This is while maintaining a healthy cash position of around 20-25% throughout most of the quarter. If we take a closer look, our gold, sliver, and mini...

ROCKVILLE, Md., June 26, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced that earlier today it sued generic drug maker Ap...

Supernus ( SUPN ) is a company that I have not previously evaluated in any detail. Recently, it has made some moves that have drawn my attention. This article evaluates these developments and their impact on its investment merit. Supernus' longstanding growth comes under threat. As a newco...

ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the closing of the acquisition of the CNS ...

ROCKVILLE, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present ...

Supernus Pharmaceuticals ( SUPN ) is a commercial-stage biopharma focused on treating CNS diseases. Supernus has been profitable each year since 2015, but the company has traded at a low earnings multiple lately due to concerns about future growth after a late-stage clinical failure last year....

ROCKVILLE, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that on May 14, 2020 the Company ...

Image source: The Motley Fool. Supernus Pharmaceuticals Inc   (NASDAQ: SUPN) Q1 2020 Earnings Call May 7, 2020 , 9:00 p.m. ET Operator Continue reading